Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology
Open Access
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (4) , 1519-1523.e9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Human IgE is efficiently produced in glycosylated and biologically active form in lepidopteran cellsMolecular Immunology, 2016
- Comparison of procainamide and 2-aminobenzamide labeling for profiling and identification of glycans by liquid chromatography with fluorescence detection coupled to electrospray ionization–mass spectrometryAnalytical Biochemistry, 2015
- Changes to Serum Sample Tube and Processing Methodology Does Not Cause Inter-Individual Variation in Automated Whole Serum N-Glycan Profiling in Health and DiseasePLOS ONE, 2015
- A single glycan on IgE is indispensable for initiation of anaphylaxisJournal of Experimental Medicine, 2015
- Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylationJournal of Biotechnology, 2014
- A tool kit for rapid cloning and expression of recombinant antibodiesScientific Reports, 2014
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- A study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer?Biotechnology and Bioengineering, 2008
- Disulfide Linkage Controls the Affinity and Stoichiometry of IgE Fcϵ3–4 Binding to FcϵRIJournal of Biological Chemistry, 2005
- RBL cells expressing human FcεRI are a sensitive tool for exploring functional IgE–allergen interactions: studies with sera from peanut-sensitive patientsJournal of Immunological Methods, 2003